ArticleArchives of virology2026
Accumulating evidence, persistent uncertainty: Leishmania RNA virus 2 in Old-World cutaneous leishmaniasis - from detection to decision-useful surveillance.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmania RNA virus 2 (LRV2) has emerged as a potential molecular co-determinant of clinical outcomes in Leishmania major infections, particularly within the Old-World cutaneous leishmaniasis (CL) belt. Recent molecular investigations from Iran and adjacent endemic regions (2024-2025) have revealed extensive LRV2 diversity and phylogeographic structure. However, the lack of standardized assays, incomplete clinical metadata, and inconsistent reporting frameworks have hindered translation of detection findings into actionable public-health insights. This commentary synthesizes these findings and proposes a six-point, standards-based micro-protocol for harmonizing molecular detection, metadata collection, and clinical outcome recording, aimed at enhancing decision-useful surveillance and global comparability.
Indexed as
Identifiers
41501391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.